| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
AIT 082 manufacturers
- Leteprinim
-
- $89.00
-
2026-08-20
- CAS:138117-50-7
- Purity: 99.08%
- Supply Ability: 10g
|
| | AIT 082 Basic information |
| Product Name: | AIT 082 | | Synonyms: | AIT 082;4-[3-(6-oxo-3H-purin-9-yl)propanoylamino]benzoic acid;Leteprinim;AIT 082 acid;NEOTROFIN; AIT-082;Benzoic acid, 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]- | | CAS: | 138117-50-7 | | MF: | C15H13N5O4 | | MW: | 327.29 | | EINECS: | | | Product Categories: | | | Mol File: | 138117-50-7.mol |  |
| | AIT 082 Chemical Properties |
| Melting point | 319-321°. | | Boiling point | 825.1±55.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | pka | 4.31±0.10(Predicted) |
| | AIT 082 Usage And Synthesis |
| Uses | Leteprinim (AIT-082 free acid), a purine analog, is a neuroprotective agent and cognitive enhancer. Leteprinim is a hypoxanthine derivative neurotrophic agent. Leteprinim can induce brain-derived neurotrophic factor (BDNF) mRNA production following spinal cord lesions, and nerve growth factor (NGF) mRNA production in basal forebrain. Leteprinim reduces glutamate toxicity in cultured hippocampal neurons. Leteprinim increases heme-oxygenase 1 and 2 mRNA levels that play role in cellular defense against reactive oxygen species[1][2][3][4]. | | Definition | ChEBI: Leteprinim is an amidobenzoic acid. | | in vivo | Leteprinim (30 or 60 mg/kg, i.p., for 7 days) protect rats against Kainate (12 mg/kg) induced excitotoxicity of hippocampal neurons[1].
Leteprinim (60 mg/kg, i.p.) enhances working memory in young and aged mice[3].
Leteprinim (60 mg/kg; i.p.; single dosage) significantly reduces the number of apoptotic neurons in hypoxic-ischemic brain injury rat pups[4]. | Animal Model: | Wistar rat pups (hypoxic-ischemic brain injury induced by permanent unilateral carotid ligation)[4] | | Dosage: | 60 mg/kg | | Administration: | IP; single dosage | | Result: | The number of preserved neurons was significantly high in CA1, CA3 regions of hippocampus and dentate gyrus in the left hemispheres when compared with the saline-treated group.
In the right hemisphere, neuronal densities of CA1, CA2, CA3 regions of hippocampus and dentate gyrus were significantly high in neotrofin treatment group when compared with the group given saline.
|
| | References | [1] Di Iorio P, et al. AIT-082 is neuroprotective against kainate-induced neuronal injury in rats. Exp Neurol. 2001 Jun;169(2):392-9. DOI:10.1006/exnr.2001.7654
[2] Lahiri DK, et al. Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin. Ann N Y Acad Sci. 2000 Apr;903:387-93. DOI:10.1111/j.1749-6632.2000.tb06390.x
[3] Glasky AJ, et al. Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav. 1994 Feb;47(2):325-9. DOI:10.1016/0091-3057(94)90017-5
[4] Gencpnar P, et al. Effects of neotrofin on neonatal hypoxic ischemic brain injury. Neurosci Lett. 2011 Nov 14;505(2):205-10. DOI:10.1016/j.neulet.2011.10.027 |
| | AIT 082 Preparation Products And Raw materials |
|